Key Highlights
- On March 31, 2026, ARK Invest acquired approximately $240 million in OpenAI Group stock distributed among three exchange-traded funds
- The same day marked OpenAI’s record-breaking $122 billion funding round, establishing an $852 billion company valuation
- ARK simultaneously increased holdings in CoreWeave and DoorDash through strategic purchases
- The firm divested more than 600,000 Strata Critical Medical shares while reducing Veracyte and Teradyne positions
- This marks the first instance where retail ETF investors gain indirect exposure to a private enterprise through ARK’s publicly available funds
Cathie Wood’s investment management firm, ARK Invest, executed one of its most substantial single-session transactions on March 31, 2026, acquiring approximately $240 million in OpenAI Group equity distributed across three actively managed exchange-traded funds.
The allocation was distributed among the ARK Innovation ETF, ARK Next Generation Internet ETF, and ARK Blockchain and Fintech Innovation ETF. Following these transactions, each portfolio maintains approximately 3% ownership in OpenAI Group PBC, Series C securities.
Prior to this strategic deployment, only ARK’s private Venture Fund maintained OpenAI exposure. That particular fund initiated its position in 2024, subsequently adding a substantial $250 million commitment in October of that same year.
ARK’s transaction coincided precisely with a landmark capital raise announcement from OpenAI. The artificial intelligence company finalized its most significant financing event to date at $122 billion, elevating its enterprise valuation to $852 billion.
According to OpenAI’s statements, the capital infusion will finance semiconductor acquisitions, infrastructure expansion including data centers, and talent recruitment. Additionally, the organization facilitated approximately $3 billion in direct share sales to individual participants through a private placement orchestrated by three leading financial institutions.
OpenAI’s Chief Financial Officer Sarah Friar articulated the company’s intention to extend investment opportunities beyond merely technological access, emphasizing the desire to share potential financial returns with retail participants.
Implications of ARK’s OpenAI ETF Integration for Individual Investors
By incorporating OpenAI securities into publicly accessible ETFs, ARK Invest has created an unconventional pathway for mainstream investors to obtain exposure to a privately held enterprise. This development represents a departure from traditional investment structures, as retail participants typically lack pre-IPO access to private company equity.
However, this structure presents valuation complexities. While ETFs maintain continuous trading throughout market hours, private securities lack transparent, real-time pricing mechanisms. Portfolio managers must rely on periodic valuations to assess these holdings, and may require liquidating more liquid positions to accommodate shareholder redemptions.
Cathie Wood addressed the transaction, noting that within the fintech ecosystem, agentic artificial intelligence will unlock extraordinary investment possibilities.
Additional Portfolio Adjustments Made by ARK on March 31
Beyond the OpenAI acquisition, ARK purchased 26,515 shares of CoreWeave, a cloud computing infrastructure provider, representing approximately $2.05 million in value. CoreWeave’s stock appreciated 12% during that trading session.
ARK also expanded its DoorDash position by acquiring 14,729 shares valued at $2.21 million. This purchase represented the second consecutive day of DoorDash accumulation, strengthening ARK’s exposure to the food delivery industry.
Regarding divestments, ARK liquidated 612,483 shares of Strata Critical Medical, generating $2.56 million in proceeds. The healthcare logistics company specializes in delivering urgent medical services and supplies to healthcare facilities throughout the United States.
The firm additionally sold 6,204 Teradyne shares for $1.84 million and disposed of 115,718 Veracyte shares across its ARKK and ARKG portfolios, totaling $3.52 million. ARK had been systematically reducing its Veracyte allocation throughout the preceding week.
The OpenAI financing round concluded with an $852 billion valuation assessment on March 31, 2026, precisely synchronized with ARK’s $240 million deployment across its three primary ETF vehicles.
